TY  - JOUR
A1  - van Oorschot, Birgitt
A1  - Rades, Dirk
A1  - Lordick, Florian
T1  - Connections Are Clearly More Complex
JF  - Deutsches Ärzteblatt international
N2  - No abstract available.
KW  - palliative medicine
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-128837
VL  - 110
IS  - 44
ER  - 
TY  - JOUR
A1  - Kuon, Jonas
A1  - Blasi, Miriam
A1  - Unsöld, Laura
A1  - Vogt, Jeannette
A1  - Mehnert, Anja
A1  - Alt-Epping, Bernd
A1  - Oorschot, Birgitt van
A1  - Sistermanns, Jochen
A1  - Ahlborn, Miriam
A1  - Ritterbusch, Ulrike
A1  - Stevens, Susanne
A1  - Kahl, Christoph
A1  - Ruellan, Anne
A1  - Matthias, Kathrin
A1  - Kubin, Thomas
A1  - Stahlhut, Kerstin
A1  - Heider, Andrea
A1  - Lordick, Florian
A1  - Thomas, Michael
T1  - Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study
JF  - Supportive Care in Cancer
N2  - Purpose
The purpose of this study is to investigate changes over time in quality of life (QoL) in incurable lung cancer patients and the impact of determinants like molecular alterations (MA).

Methods
In a prospective, longitudinal, multicentric study, we assessed QoL, symptom burden, psychological distress, unmet needs, and prognostic understanding of patients diagnosed with incurable lung cancer at the time of the diagnosis (T0) and after 3 (T1), 6 (T2) and 12 months (T3) using validated questionnaires like FACT-L, National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT), PHQ-4, SCNS-SF-34, and SEIQoL.

Results
Two hundred seventeen patients were enrolled, 22 (10%) with reported MA. QoL scores improved over time, with a significant trend for DT, PHQ-4, and SCNS-SF-34. Significant determinants for stable or improving scores over time were survival > 6 months, performance status at the time of diagnosis, and presence of MA. Patients with MA showed better QoL scores (FACT-L at T1 104.4 vs 86.3; at T2 107.5 vs 90.0; at T3 100.9 vs 92.8) and lower psychological distress (NCCN DT at T1 3.3 vs 5; at T2 2.7 vs 4.5; at T3 3.7 vs 4.5; PHQ-4 at T1 2.3 vs 4.1; at T2 1.7 vs 3.6; at T3 2.2 vs 3.6), but also a worsening of the scores at 1 year and a higher percentage of inaccurate prognostic understanding (27 vs 17%) compared to patients without MA.

Conclusion
Patients with tumors harboring MA are at risk of QoL deterioration during the course of the disease. Physicians should adapt their communication strategies in order to maintain or improve QoL.
KW  - lung cancer
KW  - quality of life
KW  - molecular alterations
KW  - prognostic awareness
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-308211
SN  - 0941-4355
SN  - 1433-7339
VL  - 30
IS  - 4
ER  - 
TY  - JOUR
A1  - Knödler, Maren
A1  - Körfer, Justus
A1  - Kunzmann, Volker
A1  - Trojan, Jörg
A1  - Daum, Severin
A1  - Schenk, Michael
A1  - Kullmann, Frank
A1  - Schroll, Sebastian
A1  - Behringer, Dirk
A1  - Stahl, Michael
A1  - Al-Batran, Salah-Eddin
A1  - Hacker, Ulrich
A1  - Ibach, Stefan
A1  - Lindhofer, Horst
A1  - Lordick, Florian
T1  - Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
JF  - British Journal of Cancer
N2  - Background
Peritoneal carcinomatosis (PC) represents an unfavourable prognostic factor for patients with gastric cancer (GC). Intraperitoneal treatment with the bispecific and trifunctional antibody catumaxomab (EpCAM, CD3), in addition to systemic chemotherapy, could improve elimination of PC.

Methods
This prospective, randomised, phase II study investigated the efficacy of catumaxomab followed by chemotherapy (arm A, 5-fluorouracil, leucovorin, oxaliplatin, docetaxel, FLOT) or FLOT alone (arm B) in patients with GC and PC. Primary endpoint was the rate of macroscopic complete remission (mCR) of PC at the time of second diagnostic laparoscopy/laparotomy prior to optional surgery.

Results
Median follow-up was 52 months. Out of 35 patients screened, 15 were allocated to arm A and 16 to arm B. mCR rate was 27% in arm A and 19% in arm B (p = 0.69). Severe side effects associated with catumaxomab were nausea, infection, abdominal pain, and elevated liver enzymes. Median progression-free (6.7 vs. 5.4 months, p = 0.71) and overall survival (13.2 vs. 13.0 months, p = 0.97) were not significantly different in both treatment arms.

Conclusions
Addition of catumaxomab to systemic chemotherapy was feasible and tolerable in advanced GC. Although the primary endpoint could not be demonstrated, results are promising for future investigations integrating intraperitoneal immunotherapy into a multimodal treatment strategy.
KW  - cancer immunotherapy
KW  - gastric cancer
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-325938
VL  - 119
ER  -